Opinion|Videos|September 10, 2024
Closing
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, discusses how minimally invasive surgical therapies (MIST) are increasingly integrated into the treatment landscape for benign prostatic hyperplasia (BPH), addressing unmet needs and offering new options, while also highlighting ongoing trials and investigations that aim to further refine these approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do minimally invasive surgical therapies (MIST) options fit into the evolving landscape of treatments for benign prostate dysplasia; why should urologists consider MIST options for their patients?
- What unmet needs remain in the treatment of BPH, and are there any current trials/investigations in these topics?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
4
FDA approves first-line Zenflow system for the treatment of BPH
5
